UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 121

Sortiert nach

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

The New England journal of medicine, 2015-07, Vol.373 (2), p.123-135

2015

Volltextzugriff (PDF)

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

The lancet oncology, 2012, Vol.13 (1), p.33-42

2012

Volltextzugriff (PDF)

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

The lancet oncology, 2010-07, Vol.11 (7), p.619-626

2010

Volltextzugriff (PDF)

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro

BMC cancer, 2019-01, Vol.19 (1), p.108-12, Article 108

2019

Volltextzugriff (PDF)

Machine learning reveals a PD-L1–independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context

European journal of cancer (1990), 2020-11, Vol.140, p.76-85

2020

Volltextzugriff (PDF)

Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2011-12, Vol.29 (34), p.4574-4580

2011

Volltextzugriff (PDF)

DNA methylation of PTGER4 in peripheral blood plasma helps to distinguish between lung cancer, benign pulmonary nodules and chronic obstructive pulmonary disease patients

European journal of cancer (1990), 2021-04, Vol.147, p.142-150

2021

Volltextzugriff (PDF)

Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study

Journal of clinical oncology, 2009-05, Vol.27 (15), p.2523-2529

2009

Volltextzugriff (PDF)

First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study

The lancet oncology, 2011, Vol.12 (1), p.30-37

2011

Volltextzugriff (PDF)

Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2008-11, Vol.26 (33), p.5407-5415

2008

Volltextzugriff (PDF)

Long-Term Survival in Patients with Oligometastatic Non-Small Cell Lung Cancer by a Multimodality Treatment-Comparison with Stage III Disease

Cancers, 2024-03, Vol.16 (6), p.1174

2024

Volltextzugriff (PDF)

Long-term survival of patients with central or > 7 cm T4 N0/1 M0 non-small-cell lung cancer treated with definitive concurrent radiochemotherapy in comparison to trimodality treatment

Radiation oncology (London, England), 2022-07, Vol.17 (1), p.1-126, Article 126

2022

Volltextzugriff (PDF)

Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study

BMC cancer, 2018-02, Vol.18 (1), p.135-135, Article 135

2018

Volltextzugriff (PDF)

Neoadjuvant and adjuvant end-points in health technology assessment in oncology

European journal of cancer (1990), 2021-04, Vol.147, p.40-50

2021

Volltextzugriff (PDF)

68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study

The Journal of nuclear medicine (1978), 2023-10, Vol.64 (10), p.1540-1549

2023

Volltextzugriff (PDF)

MET Expression in Advanced Non–Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy

Clinical lung cancer, 2018-07, Vol.19 (4), p.e441-e463

2018

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012

Journal of thoracic oncology, 2013-03, Vol.8 (3), p.373-384

2013

Volltextzugriff (PDF)

The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer

Journal of thoracic oncology, 2015-11, Vol.10 (11), p.1515-1522

2015

Volltextzugriff (PDF)

History Can Teach Us Something: Angiogenesis Inhibition Revisited

Journal of thoracic oncology, 2024-06, Vol.19 (6), p.849-851

2024

Volltextzugriff (PDF)

Patterns of nodal spread in stage III NSCLC: importance of EBUS-TBNA and 18F-FDG PET/CT for radiotherapy target volume definition

Radiation oncology (London, England), 2021-09, Vol.16 (1), p.1-176, Article 176

2021

Volltextzugriff (PDF)

Inhibiting the Aurora B Kinase Potently Suppresses Repopulation During Fractionated Irradiation of Human Lung Cancer Cell Lines

International journal of radiation oncology, biology, physics, 2012-10, Vol.84 (2), p.492-499

2012

Volltextzugriff (PDF)

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

Journal of clinical oncology, 2015-12, Vol.33 (34), p.4007-4014

2015

Volltextzugriff (PDF)

Too Good to be True?

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.507-508

2021

Volltextzugriff (PDF)

1 – 25 von 121

Suche als RSS-Feed

Aktive Filter

KollektionNature Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(115)
Mit Volltextzugriff
(118)

Publikationsform

Artikel
(120)
Tagungsberichte
(1)

Sprache

Englisch
(117)
Japanisch
(18)
Deutsch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(95)
Science & Technology
(95)
Oncology
(83)
Humans
(78)
Lung Neoplasms - Pathology
(48)
Male
(46)
Female
(45)
Middle Aged
(39)
Respiratory System
(38)
Aged
(37)
Lung Cancer
(35)
Lung Neoplasms - Drug Therapy
(32)
Carcinoma, Non-Small-Cell Lung - Pathology
(31)
Adult
(30)
Neoplasm Staging
(30)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(28)
Prognosis
(26)
Tumors
(24)
Aged, 80 And Over
(19)
Biological And Medical Sciences
(18)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro

Machine learning reveals a PD-L1–independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context

Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non–Small-Cell Lung Cancer

DNA methylation of PTGER4 in peripheral blood plasma helps to distinguish between lung cancer, benign pulmonary nodules and chronic obstructive pulmonary disease patients

Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study

First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study

Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

Long-Term Survival in Patients with Oligometastatic Non-Small Cell Lung Cancer by a Multimodality Treatment-Comparison with Stage III Disease

Long-term survival of patients with central or > 7 cm T4 N0/1 M0 non-small-cell lung cancer treated with definitive concurrent radiochemotherapy in comparison to trimodality treatment

Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study

Neoadjuvant and adjuvant end-points in health technology assessment in oncology

68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study

MET Expression in Advanced Non–Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy

Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012

The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

History Can Teach Us Something: Angiogenesis Inhibition Revisited

Patterns of nodal spread in stage III NSCLC: importance of EBUS-TBNA and 18F-FDG PET/CT for radiotherapy target volume definition

Inhibiting the Aurora B Kinase Potently Suppresses Repopulation During Fractionated Irradiation of Human Lung Cancer Cell Lines

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

Too Good to be True?

Aktive Filter

Suchergebnisse filtern